Literature DB >> 14716157

Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department.

Marlene D Melzer-Lange1, Christine M Walsh-Kelly, Gwen Lea, Cheryl A Hillery, J Paul Scott.   

Abstract

OBJECTIVE: To determine whether a protocol to start patient-controlled analgesia (PCA) in the emergency department (ED-PCA) would shorten the length of time between narcotic bolus doses and PCA initiation as compared with standard inpatient initiation of PCA (IP-PCA). Also, to compare patient satisfaction and inpatient length of stay for the 2 groups.
METHODS: To improve care, we developed a protocol to institute ED-PCA after an initial bolus dose of narcotics. This was a nonrandomized pilot study. Patient records were reviewed for location of PCA initiation, time from narcotic bolus to initiation of PCA, and length of stay. A brief patient/parent satisfaction survey was collected.
RESULTS: Sixty-nine records were reviewed. Patients treated using the protocol had initiation of PCA therapy within 35 +/- 7 minutes from the last bolus narcotic dose in the emergency department versus 211 +/- 17 minutes for nonprotocol patients. Forty-eight of 50 patient surveys indicated preference for starting ED-PCA; 2 did not have a preference. No complications were identified in either group.
CONCLUSIONS: A protocol to initiate PCA for sickle cell patients in a pediatric emergency department shortened the time of its initiation and was preferred by patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14716157     DOI: 10.1097/01.pec.0000106235.72265.29

Source DB:  PubMed          Journal:  Pediatr Emerg Care        ISSN: 0749-5161            Impact factor:   1.454


  10 in total

Review 1.  The management of sickle cell pain.

Authors:  Robert E Richard
Journal:  Curr Pain Headache Rep       Date:  2009-08

2.  Patient-controlled analgesia at the end of life at a pediatric oncology institution.

Authors:  Doralina L Anghelescu; Jennifer M Snaman; Luis Trujillo; April D Sykes; Y Yuan; Justin N Baker
Journal:  Pediatr Blood Cancer       Date:  2015-03-27       Impact factor: 3.167

3.  Clinical Pathway for Vaso-Occlusive Pain Reduces Hospital Admissions.

Authors:  Wallace Jones; Albert Jang; Leann Myers; Aditi Dasgupta; Jessica DeBord
Journal:  J Healthc Qual       Date:  2022 Jan-Feb 01       Impact factor: 1.095

Review 4.  Key Components of Pain Management for Children and Adults with Sickle Cell Disease.

Authors:  Amanda M Brandow; Michael R DeBaun
Journal:  Hematol Oncol Clin North Am       Date:  2018-06       Impact factor: 3.722

5.  Use of patient-controlled analgesia for pain control in dying children.

Authors:  Christine Schiessl; Chara Gravou; Boris Zernikow; Reinhard Sittl; Norbert Griessinger
Journal:  Support Care Cancer       Date:  2008-02-15       Impact factor: 3.603

6.  [Circadian rhythm of PCA-based opioid consumption in children with chemotherapy-related mucositis].

Authors:  C Schiessl; I Schestag; N Griessinger; R Sittl; B Zernikow
Journal:  Schmerz       Date:  2009-02       Impact factor: 1.107

Review 7.  Pediatric palliative care: use of opioids for the management of pain.

Authors:  Boris Zernikow; Erik Michel; Finella Craig; Brian J Anderson
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

8.  Analgesic Response to Morphine in Children with Sickle Cell Disease: A Pilot Study.

Authors:  Eufemia Jacob; Marilyn Hockenberry; Brigitta U Mueller; Thomas D Coates; Lonnie Zeltzer
Journal:  J Pain Manag       Date:  2008

9.  Implementation strategies in emergency management of children: A scoping review.

Authors:  Alex Aregbesola; Ahmed M Abou-Setta; George N Okoli; Maya M Jeyaraman; Otto Lam; Viraj Kasireddy; Leslie Copstein; Nicole Askin; Kathryn M Sibley; Terry P Klassen
Journal:  PLoS One       Date:  2021-03-24       Impact factor: 3.240

10.  Patient Controlled Analgesia for Adults with Sickle Cell Disease Awaiting Admission from the Emergency Department.

Authors:  Josue Santos; Sasia Jones; Daniel Wakefield; James Grady; Biree Andemariam
Journal:  Pain Res Manag       Date:  2016-03-29       Impact factor: 3.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.